When melatonin gets on your nerves: Its beneficial actions in experimental models of stroke

Experimental Biology and Medicine

Volumn 230, Issue 2, 2005, Pages 104-117

  Reiter, Russel J ^a   Tan, Dun Xian ^a   Leon, Josefa ^a   Kilic, Ülkan ^b   Kilic, Ertugrul ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antioxidant; Brain oxidative stress; Free radicals; Ischemia reperfusion injury; Melatonin; Stroke

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; DNA; FREE RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELATONIN; OXIDOREDUCTASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; CELL MEMBRANE; DETOXIFICATION; DNA DAMAGE; EDEMA; HUMAN; ISCHEMIA; LIPID PEROXIDATION; MITOCHONDRION; NERVE INJURY; NEUROPHYSIOLOGY; NEUROPROTECTION; OXIDATIVE PHOSPHORYLATION; PROTEIN DNA BINDING; PROTEIN INTERACTION; PROTEIN SYNTHESIS; REPERFUSION INJURY; SHORT SURVEY; STROKE; TISSUE INJURY;

ANIMALIA;

EID: 12744273107     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020523000205     Document Type: Short Survey

References (140)

1. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Mason JE, Rosner B, Speizer FE, Hennekens CH. Smoking cessation and decreased risk of stroke in women. J Am Med Assoc 269:232-236, 1993.
2. Mac Mahon S, Rodgers A. The epidemiological association between blood pressure and stroke: implications for primary and secondary prevention. Hyperten Res 17 (Suppl):523-532, 1994.
3. Wolf PA. Epidemiology and risk factor management. In: Welch KMA, Caplan LR, Reis DJ, Siesjö BK, Weir B, Eds. Primer on Cerebrovascular Diseases. San Diego: Academic Press, pp751-757, 1997.
4. Ginsburg MD. Animal models of global and focal cerebral ischemia. In: Welch KMA, Caplan LR, Reis DJ, Siesjö BK, Weir B, Eds. Primer on Cerebrovascular Diseases. San Diego: Academic Press, pp124-126, 1997.
5. Mazziotta J, Cohen M, Toga A. The measurement of cerebral blood flow and metabolism in human subjects. In: Welch KMA, Caplan LR, Reis DJ, Siesjö BK, Weir B, Eds. Primer on Cerebrovascular Diseases. San Diego: Academic Press, pp34-37, 1997.
6. Pulsinelli WA. Selective neuronal vulnerability: morphological and molecular characteristics. Prog Brain Res 53:29-37, 1985.
7. Pulsinelli WA. Selective neuronal vulnerability and infarction in Cerebrovascular disease. In: Welch KMA, Caplan LR, Reis DJ, Siesjö BK, Weir B, Eds. Primer on Cerebrovascular Diseases. San Diego: Academic Press. pp104-107, 1997.
8. Nagel E, Meyer zu Vilsendorf A, Bontels M, Pichlmayr R. Antioxidant vitamins in prevention of ischemia/reperfusion injury. Int J Vit Nutr Res 67:298-306, 1997.
9. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine (3rd ed.). Oxford: Oxford University Press, 2000.
10. Hassman KA. Mechanisms of ischemic injury: is glutamate involved? In: Krieglstein J, Oberpichler-Schwenk H, Eds. Pharmacology of Cerebral Ischemia. Stuttgart: Medpharm Publishers, pp239-251, 1994.
11. Globus MYT, Prado R, Sanchez-Ramos J, Dietrich WD, Ginsberg MD, Busto R. Excitotoxic and ischemic damage: role of nitric oxide. In: Krieglstein J, Oberpichler-Schwenk H, Eds. Pharmacology of Cerebral Ischemia. Stuttgart: Medpharm Publishers, pp363-374, 1994.
12. Hayashi N, Otuki R, Tamura A. Effects of MS-153 on free radical reactions in cerebral ischemia. In: Krieglstein J, Oberpichler-Schwenk H, Eds. Pharmacology of Cerebral Ischemia. Stuttgart: Medpharm Publishers, pp361-365, 1994.
13. Choi DW. Calcium-mediated neurotoxicity: relationship to specific channel types and role of ischemic damage. Trends Neurosci 11:465-469, 1988.
14. Katayama Y, Kawamata T, Maeda T, Ishikawa K, Tsubokawa T. Inhibition of the early phase of free fatty acid liberation during cerebral ischemia by excitatory amino acid antagonist administered by microdialysis. Brain Res 635:331-334, 1994.
15. Hardeland R, Reiter RJ, Poeggeler B, Tan DX. The significance of the metabolism of the neurohormone melatonin: antioxidative protection and formation of bioactive substances. Neurosci Biobehav Res 17:347-357, 1993.
16. Poeggeler B, Reiter RJ, Tan DX, Chen LD, Manchester LC. Melatonin, hydroxyl radical-mediated oxidative damage and aging: a hypothesis. J Pineal Res 14:151-158, 1993.
17. Reiter RJ. Functional aspects of the pineal hormone melatonin in combatting cell and tissue damage induced by free radicals: a review. Eur J Endocrinol 134:412-420, 1996.
18. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 34:237-256, 2001.
19. Tan DX, Reiter RJ, Manchester LC, Van MT, El-Sawi M, Sainz RM, Mayo JC, Kohen R, Allegra M, Hardeland R. Chemical and physical properties and potential mechanism: melatonin as a broad-spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2:181-198, 2002.
20. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA. The chemistry of melatonin's interaction with reactive species. J Pineal Res 34:1-10, 2003.
21. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci 7:444-458, 2001.
22. Acua-Castroviejo D, Martin M, Macias M, Escames G, Leon J, Khaldy H, Reiter RJ. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 30:65-74, 2001.
23. Acua-Castroviejo D, Escames G, Carozo A, Leon J, Khaldy H, Reiter RJ. Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. Curr Top Med Chem 2:133-152, 2002.
24. Rodriquez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V. Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 36:1-9, 2004.
25. Reiter RJ. Melatonin: lowering the high price of free radicals. News Physiol Sci 15:246-250, 2001.
26. Reiter RJ, Tan DX. Melatonin: a novel protective agent against oxidative injury of the ischemic/reperfused heart. Cardiovasc Res 58:10-19, 2003.
27. Sewerynek E, Reiter RJ, Melchiorri D, Ortiz GG, Lewinski A. Oxidative damage in the liver induced by ischemia-reperfusion: protection by melatonin. Hepatogastroenterology 43:898-905, 1996.
28. Okatani Y, Wakatsuki A, Reiter RJ, Enzan H, Miyahara Y. Protective effect of melatonin against mitochondrial injury induced by ischemia and reperfusion of rat liver. Eur J Pharmacol 469:145-152, 2003.
29. Brzozowski T, Konturek PC, Konturek SJ, Pajdo R, Bielanski W, Brzozowski, Stachura J, Hahn EG. The role of melatonin and L-tryptophan in prevention of acute gastric lesions induced by stress, ethanol, ischemia and aspirin. J Pineal Res 23:79-89, 1997.
30. Inci I, Inci D, Dutly A, Boehler A, Weder W. Melatonin attenuates post transplant lung ischemia-reperfusion injury. Ann Thorac Surg 73:220-225, 2002.
31. Kilic E, Özdemir YG, Bolay H, Kelestimur H, Dalkara I. Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. J Cerebr Blood Flow Metab 19:511-516, 1999.
32. Kilic E, Hermann DM, Isenmann S, Bohr M. Effects of pinealectomy and melatonin on the retrograde degeneration of retinal ganglion cells in a novel model of intraorbital optic nerve transection in mice. J Pineal Res 32:106-111, 2002.
33. Sener G, Sehirli AO, Keyer-Uysal M, Arbak S, Ersoy Y, Yegen BC. The protective effect of melatonin on renal ischemia-reperfusion injury in the rat. J Pineal Res 32:120-126, 2002.
34. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 12:151-180, 1991.
35. Faillace MP, Cutrera R, Keller-Sarmento MI, Rosenstein RE. Evidence for local synthesis of melatonin in golden hamster retina. Neuroreport 6:2093-2095, 1995.
36. Huether G, Poeggeler B, Reimer A, George A. Effect of tryptophan administration on circulating melatonin levels in checks and rats: evidence for stimulation of melatonin synthesis and release in the gastrointestinal tract. Life Sci 52:945-953, 1992.
37. Bubenik GA. Gastrointestinal melatonin: localization, function and clinical relevance. Dig Dis Sci 47:2336-2348, 2002.
38. Tan DX, Manchester LC, Reiter RJ, Qi W, Zhang M, Weintraub ST, Cabrera J, Sainz RM, Mayo JC. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1472:206-214, 1999.
39. Conti A, Conconi S, Hertens E, Skwarlo-Sonta K, Markowska M, Maestroni GJM. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 28:193-202, 2000.
40. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, Garcia-Morino S, Reiter RJ, Guerrero JM. Evidence of melatonin synthesis in human lymphocytes and its physiological significance: possible role as intracrine, autocrine and/or paracrine substance. FASEB J 18:537-539, 2004.
41. Slominski A, Pisarchik A, Semak I, Sweatman T, Wortsman J, Szczesniewski A, Slugocki G, McNulty J, Kauser S, Tobin DI, Jing C, Johansson O. Serotoninergic and melatoninergic systems are fully expressed in human skin. FASEB J 16:896-898, 2002.
42. Lopez-Gonzalez MA, Guerrero JM, Delgado F. Presence of the pineal hormone in rat cochlea: its variations with lighting conditions. Neurosci Lett 238:81-83, 1997.
43. Abe M, Itoh MT, Miyata M, Shimizu K, Sumi Y. Circadian rhythm of serotonin N-acetyltransferase activity in rat lens. Exp Eye Res 70:805-808, 2000.
44. Stefulj J, Hörtner M, Ghosh M, Schauenstein K, Rinner I, Wölfer A, Semmler J, Liebmann PM. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res 30:243-247, 2001.
45. Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Oktani-Kandro R, Hara M, Suzuki T, Reiter RJ. Identification of melatonin in plants: its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int 35:627-634, 1995.
46. Reiter RJ, Tan DX, Burkhardt S, Manchester LC. Melatonin in plants. Nutr Rev 59:286-290, 2001.
47. Tan DX, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM, Reiter RJ. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 34:75-78, 2003.
48. Reiter RJ, Vaughan MK, Blask DE. Possible role of the cerebrospinal fluid in the transport of pineal hormones in mammals. In: Knigge KM, Scott DE, Koboyashi H, Ishii S, Eds. Brain-Endocrine Interaction II. Basel: Karger, pp337-354, 1975.
49. Skinner DC, Malpaux B. High melatonin concentrations in third ventricular cerebrospinal fluid are not due to Galen vein blood recirculating through the choroid plexus. Endocrinology 140:4399-4405, 1999.
50. Tricoire H, Locatelli A, Chemineau P, Malpaux B. Melatonin enters cerebrospinal fluid through the pineal recess. Endocrinology 143:184-190, 2002.
51. Tan DX, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ. High physiological levels of melatonin in bile of mammals. Life Sci 65:2523-2529, 1999.
52. Brzezinski A, Seibel MM, Lynch HJ, Deng MH, Wurtman RJ. Melatonin in human preovulatory follicular fluid. J Clin Endocrinol Metab 64:865-867, 1987.
53. Antolin I, Obst B, Burkhardt S, Hardeland R. Antioxidant properties in a high-melatonin organism: the dinoflagellate Gonyaulax polyedra is rescued from lethal oxidative stress by strongly elevated, but physiologically possible concentrations of melatonin. J Pineal Res 23:182-190, 1997.
54. Spencer J, Hardeland R, Fuhrberg B. Melatonin and other methoxylated indoles in yeast: presence in high concentrations and dependence on tryptophan availability. Cytologia 64:209-213, 1999.
55. Martin M, Macias M, Escames G, Leon J, Acua-Castroviejo D. Melatonin but not vitamins C and E maintain glutathione hemostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress. FASEB J 14:1677-1679, 2000.
56. Menendez-Pelaez A, Poeggeler B, Reiter RJ, Barlow-Walden L, Pablos MI, Tan DX. Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence: J Cell Biochem 53:373-382, 1993.
57. Reiter RJ, Tan DX. What constitutes a physiological concentration of melatonin? J Pineal Res 34:79-80, 2003.
58. Menendez-Pelaez A, Reiter RJ. Distribution of melatonin in mammalian tissues: relative importance of nuclear verses cytosolic localization. J Pineal Res 15:59-69, 1993.
59. Reiter RJ, Burkhardt S, Cabrera J, Garcia JJ. Beneficial neurobiological effects of melatonin under conditions of increased oxidative stress. Curr Med Chem 2:45-58, 2002.
60. Baydas G, Kutlur S, Naziroglu M, Canpolat S, Sandal S, Ozcan M, Kelestimur H. Inhibitory effect of melatonin on neural lipid peroxidation induced by intracerebroventricularly administered homocysteine. J Pineal Res 34:36-39, 2003.
61. Ohta Y, Kongo M, Kishikawa T. Preventive effect of melatonin on the progression of α-naphthylisothiocyanate-induced acute liver injury in rats. J Pineal Res 34:185-193, 2003.
62. Reiter RJ, Tan DX, Kim SJ, Manchester LC, Qi W, Garcia JJ, Cabrera JC, El-Sokkary G, Rouvier-Garay V. Augmentation of indices of oxidative damage in life-long melatonin-deficient rats. Mech Aging Dev 110:157-173, 1999.
63. Okatani Y, Wakatsuki A, Reiter RJ, Miyohara Y. Melatonin reduces oxidative damage of neural lipids and proteins in senescence-associated mouse. Neurobiol Aging 23:639-644, 2002.
64. Sener G, Sehirli AO, Ayanoglu-Dülger G. Protective effect of melatonin, vitamin E and N-acetylcysteine against acetaminophen toxicity in mice: a comparative study. J Pineal Res 35:61-68, 2003.
65. Karbownik M, Reiter RJ, Burkhardt S, Tan DX, Lewinski A. Melatonin attenuates estradiol-induced oxidative damage to DNA: relevance to cancer. Exp Biol Med 226:707-712, 2001.
66. Hsu CH, Chi BC, Casida JE. Melatonin reduces phosphine-induced lipid and DNA oxidation in vitro and in vivo in rat brain. J Pineal Res 32:53-62, 2002.
67. Sun FY, Lin X, Mao LZ, Ge W, Zhang LM, Huang YL, Gu J. Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia. J Pineal Res 33:48-56, 2002.
68. Mansouri A, Demeilliers C, Amsellam S, Pessayre D, Fromenty B. Acute ethanol administration damages and depletes mitochondrial DNA in mouse liver, brain, heart and skeletal muscle: protective effects of antioxidants. J Pharmacol Exp Ther 298:737-743, 2001.
69. Yamamoto HA, Mohanan PV. Ganglioside GT1B and melatonin inhibit brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Brain Res 964:100-106, 2003.
70. Poeggeler B, Thuermann S, Rose A, Schoenke M, Burkhardt S, Hardeland R. Melatonin's unique radical scavenging properties - roles of its functional substituents as revealed by a comparison with its structural analogs. J Pineal Res 33:20-30, 2002.
71. Abel Wahab MH, Akoul EEMS, Abdel-Aziz AAH. Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich acites carcinoma-bearing mice. Tumori 86:157-162, 2000.
72. Montilla P, Cruz A, Padillo FJ, Tunez I, Gascon F, Munoz MC, Ganez M, Pera C. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats. J Pineal Res 31:138-144, 2001.
73. Baydas G, Canataan H, Turkoglu A. Comparative analysis of the protective effects of melatonin and vitamin E on streptozocin-induced diabetes mellitus. J Pineal Res 32:225-230, 2002.
74. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1:57-60, 1993.
75. Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 56:359-384, 1998.
76. Cuzzocrea S, Reiter RJ. Pharmacological action of melatonin in shock, inflammation and ischemia/reperfusion injury. Eur J Pharmacol 426:1-10, 2001.
77. Cheung RTF. The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J Pineal Res 34:153-160, 2003.
78. Reiter RJ, Sainz RM, Lopez-Burillo S, Mayo JC, Manchester LC, Tan DX. Melatonin ameliorates neurological damage and neurophysiological deficits in experimental models of stroke. Ann N Y Acad Sci 993:35-47, 2003.
79. Hirata F, Hayaishi O, Tokuyama T, Senoh S. In vitro and in vivo formation of two new metabolites of melatonin. J Biol Chem 249:1311-1313, 1974.
80. 2. J Pineal Res 34:134-142, 2003.
81. 2-formyl-5-methoxykynuramine. J Pineal Res 35:131-137, 2003.
82. 2-formyl-5-methoxykynuramine is a product of melatonin oxidation in rats. J Pineal Res 35:245-250, 2003.
83. 2-formyl-5- methoxykynuramine, resveratrol and uric acid. Int J Biochem Cell Biol 33:775-783, 2001.
84. 2-formyl-5- methoxykynuramine, a biogenic amine and melatonin metabolite, functions as a potent antioxidant. FASEB J 15:2294-2296, 2001.
85. 2-formyl-5-methoxykynuramine and 6-methoxymelatonin reduce oxidative DNA damage induced by Fenton reagents. J Pineal Res 34:178-184, 2003.
86. 1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Report 8:205-213, 2003.
87. Ianas O, Olinescu R, Badescu I. Melatonin involvement in oxidative processes. Endocrinologie 29:147-153, 1991.
88. Manev H, Uz T, Kharlamov A, Joo JY. Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats. FASEB J 10:1546-1551, 1996.
89. Joo JY, Uz T, Manev H. Opposite effects of pinealectomy and melatonin administration on brain damage following cerebral focal ischemia in rat. Rest Neurol Neurosci 13:185-191, 1998.
90. Reiter RJ. The aging pineal and its physiological consequences. Bio Essays 14:169-175, 1992.
91. Zhou JN, Liu RY, Heerikhuize JV, Hofman MA, Swaab DF. Alterations in the arcadian rhythm of salivary melatonin begin in middle-age. J Pineal Res 34:11-16, 2003.
92. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res 35:125-130, 2003.
93. Manev H, Uz T. The role of the light-dark cycle and melatonin in stroke outcome. J Stroke Cerebrovasc Dis 7:165-167, 1996.
94. Cho S, Joh TH, Baik HH, Dibinis C, Volpe BT. Melatonin administration protects CA1 hippocampal neurons after ischemia in rats. Brain Res 755:335-338, 1997.
95. Giusti P, Lipartiti M, Franceschini D, Schiavo N, Floreani M, Manev H. Neuroprotection by melatonin from kainate-induced excitotoxicity in rats. FASEB J 10:891-896, 1996.
96. Lezoualc'h F, Skutella T, Wideman M, Behl C. Melatonin prevents oxidative stress-induced cell death in hippocampal cells. Neuroreport 7:2071-2076, 1996.
97. Lezoualc'h F, Sparapani M, Behl C. N-acetylserotonin and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-κB. J Pineal Res 24:167-178, 1998.
98. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634, 1987.
99. Choi DW. The excitotoxic concept. In: Welch KMA, Caplan LR, Reis DJ, Siesjö BK, Weir B, Eds. Primer on Cerebrovascular Disease. San Diego: Academic Press, pp188-190, 1997.
100. Reiter RJ, Cabrera J, Sainz RM, Mayo JC, Manchester LC, Tan DX. Melatonin as a pharmacological agent against neuron loss in experimental models of Huntington's disease, Alzheimer's disease and Parkinsonism. Ann N Y Acad Sci 890:471-485, 2000.
101. Li XJ, Zhang LM, Gu J, Zhang AZ, Sun FJ. Melatonin decreases production of the hydroxyl radical during cerebral ischemia-reperfusion. Acta Pharmacol Sinica 18:394-396, 1997.
102. Leon J, Acua-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ. Melatonin and mitochondrial function. Life Sci(in press).
103. Ling X, Zhang LM, Lu SC, Li XJ, Sun FJ. Protective effect of melatonin on injured cerebral neurons is associated with bcl-2 overexpression. Acta Pharmacol Sin 20:409-414, 1999.
104. Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TFW. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 18:869-871, 2004.
105. Jou MJ, Peng TI, Reiter RJ, Jou SB, Wu HY, Wen ST. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res(in press).
106. Sainz RM, Mayo JC, Rodriquez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci 60:1407-1426, 2003.
107. Sinha K, Degaonkar MN, Jagannathan NR, Gupta Y. Effect of melatonin on ischemia/reperfusion injury induced by middle cerebral artery occlusion in rats. Eur J Pharmacol 428:185-192, 2002.
108. Kondoh T, Uneyama H, Nishino H, Torii K. Melatonin reduces cerebral edema formation caused by transient forebrain ischemia in rats. Life Sci 72:583-590, 2002.
109. Torii K, Uneyama H, Nishino H, Kondoh T. Melatonin suppresses cerebral edema caused by middle cerebral artery occlusion/reperfusion in rats assessed by magnetic resonance imaging. J Pineal Res 36:18-24, 2004.
110. Borlongan CV, Yamamoto M, Takei N, Kumazahi M, Ungsuparkorn C, Hida H, Sanberg PR, Nishino H. Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J 14:1307-1317, 2000.
111. Baydas G, Reiter RJ, Nedzvetskii VS, Nurush PA, Kirichendo SV. Altered glial fibrillary acidic protein content and its degradation in the hippocampus, cortex and cerebellum of rats exposed to constant light: reversal by melatonin. J Pineal Res 33:134-139, 2002.
112. Baydas G, Reiter RJ, Yasar A, Tuzcu M, Gokdemir I, Nedzvetskii VS. Melatonin reduces glial cell reactivity in the hippocampus, cortex and cerebellum of streptozotocin-induced diabetic rat. Free Radic Biol Med 35:797-804, 2003.
113. Kilic E, Kilic V, Yulug B, Hermann DM, Reiter RJ. Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator. J Pineal Res 36:171-176, 2004.
114. Cuzzocrea S, Costantino G, Gitto E, Mazzon E, Fulia F, Serraino I, Cordaro S, Barben I, De Sarro A, Caputi AP. Protective effects of melatonin in ischemic brain injury. J Pineal Res 29:217-227, 2000.
115. Guerrero JM, Reiter RJ, Ortiz GG, Pablos MI, Sewerynek E, Chuang JI. Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (Meriones unguiculatus). J Pineal Res 23:24-31, 1997.
116. Pei Z, Ho HT, Cheung RT. Pretreatment with melatonin reduces volume of cerebral infarction in a permanent middle cerebral artery occlusion stroke model in the rat. Neurosci Lett 318:141-144, 2002.
117. Pei Z, Pang SF, Cheung RP. Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. J Pineal Res 32:168-172, 2002.
118. Pei Z, Pang SF, Cheung RT. Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a middle cerebral artery occlusion stroke model. Stroke 34:770-775, 2003.
119. Pei Z, Fung PC, Cheung RT. Melatonin reduces nitric oxide level during ischemia but not blood-brain-barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model. J Pineal Res 34:110-118, 2003.
120. Wakatsuki A, Okatani Y, Izumiya C, Ikenoue N. Melatonin protects against ischemia and reperfusion-induced oxidative and lipid DNA damage in fetal rat brain. J Pineal Res 26:147-152, 1999.
121. Okatani Y, Okamoto K, Hayachi K, Wakatsuki A, Sagara Y. Maternal-fetal transfer of melatonin in human pregnancy near term. J Pineal Res 25:129-134, 1998.
122. Letechipia-Vallejo G, Gonzalez-Burgos I, Cervantes M. Neuroprotective effect of melatonin on brain damage induced by acute global cerebral ischemia in cats. Arch Med Res 32:186-192, 2001.
123. Benot S, Goberna R, Reiter RJ, Garcia-Moreno S, Osuna C, Guerrero JM. Physiological levels of melatonin correlate with the antioxidant capacity of human serum. J Pineal Res 27:59-64, 1999.
124. Cuzzocrea S, Costantino G, Mazzon R, Micali A, Sarro A, Caputi AP. Beneficial effects of melatonin in a rat model of splanchnic artery occlusion and reperfusion. J Pineal Res 28:52-63, 2000.
125. Tan DX, Manchester LC, Reiter RJ, Plummer BF, Hardies LJ, Weintraub ST, Vijayalaxmi, Shepherd AM. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 253:614-620, 1998.
126. Hara M, Iigo M, Okatani-Kaneko R, Nakamura N, Suzuki T, Reiter RJ, Hirata K. Administration of melatonin and related indoles prevents exercise-induced cellular oxidative changes in rats. Biol Signals 6:90-100, 1997.
127. Maharaj DS, Walker RB, Glass BD, Daya S. 6-hydroxymelatonin protects against cyanide induced oxidative stress in rat brain homogenates. J Chem Neuroanat 26:103-107, 2003.
128. Shaper SD, Floreani M, Ceccon M, Facci L, Giusti P. Excitotoxicity, oxidative stress and the neuroprotective potential of melatonin. Ann N Y Acad Sci 890:107-118, 1999.
129. Troiani ME, Reiter RJ, Vaughan MK, Oakin S, Vaughan GM. Swimming depresses nighttime melatonin content without changing N-acetyltransferase activity in the rat pineal gland. Neuroendocrinology 47:55-60, 1987.
130. Wu W, Reiter RJ, Troiani ME, Vaughan GM. Elevated daytime rat pineal and serum melatonin levels induced by isoproterenol are depressed by swimming. Life Sci 41:1473-1479, 1987.
131. Troiani ME, Reiter RJ, Tannenbaum MG, Puig-Domingo M, Guerrero JM, Menendez-Pelaez A. Neither the pituitary gland nor the sympathetic nervous system is responsible for eliciting the large drop in elevated rat pineal melatonin levels due to swimming. J Neural Transm 74:149-160, 1988.
132. Ueck M, Troiani ME, Reiter RJ. Transient reduction in pineal melatonin levels but not N-acetyltransferase activity in rats forced to swim for 15 minutes at night. Neuroendocr Lett 10:81-90, 1988.
133. Reiter RJ, Richardson BA. Some perturbations that disturb the circadian melatonin rhythm. Chronobiol Int 9:314-321, 1992.
134. Nordlund JJ, Lerner AB. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metab 45:768-774, 1977.
135. Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C. Maternal and developmental toxicity of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 50:271-279, 1999.
136. Jan JE, Hamilton D, Seward N, Fast DK, Freeman RD, Laudon M. Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. J Pineal Res 29:34-39, 2000.
137. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi S, Cordaro S, Corona G, Trimarchi G, Barberi I. Effects of melatonin treatment in septic newborns. Pediatr Res 50:756-760, 2001.
138. Gitto E, Reiter RJ, Amodio A, Romero C, Cuzzocrea E, Sabatino G, Buonocore G, Cordaro V, Trimarchi G, Barberi I. Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pineal Res 36:250-255, 2004.
139. Gitto E, Romeo C, Reiter RJ, Inpellizzeri R, Pesce S, Basile M, Autonuccio P, Trimarchi G, Gentile C, Barberi I, Zuscaselto B. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg 39:184-189, 2004.
140. Tan DX, Manchester LC, Sainz RM, Mayo JC, Alvares FL, Reiter RJ. Antioxidant strategies in protection against neurodegenerative disorders. Curr Opin Ther Patents 13:1513-1543, 2003.